title: Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid.
abstract: OBJECTIVE
  The aim of this study was to evaluate the response of high dose rate interstitial brachytherapy in carcinoma eye lid.
  
  
  METHODS
  From January 2004 to December 2008, 20 diagnosed cases of carcinoma eye lid were reported in our department. Lower eye lid was involved in 11 patients and upper eye lid in 9 patients. All cases were staged clinically according to the TNM staging system. All patients were treated with high dose rate interstitial implant and analyzed for presence of residual disease, local recurrence, distant metastasis, radiation reaction and disease free survival.
  
  
  RESULTS
  There was 18 (90%) and 2 (10%) patients in stage I and II, respectively. Histological 10 (50%) cases were of squamous cell carcinoma, 8 (40%) cases were of sebaceous carcinoma and 2 (10%) cases were of basal cell carcinoma. All patients received six fraction of 6.5 Gy in 6 days. Complete response was seen in all patients. The median follow up time for all patients was 39.5 months with 95% confidence interval of 30.1 to 62.6 month. The 5-year disease free survival rate was 90%, 57.14%, and 50% for squamous cell carcinoma, sebaceous cell carcinoma and basal cell carcinoma, respectively. No isolated regional lymph node metastasis and distant metastases were seen. No visual complication was seen.
  
  
  CONCLUSIONS
  The results of this study suggest that high dose rate interstitial brachytherapy was appropriate for the treatment of early staged carcinoma of eye lid.
authors.affiliation: Department of Radiotherapy, Regional Cancer Centre, Dr BRA M Hospital, Raipur 492 001, Chhattisgarh, India. drskazad@gmail.com
authors.forename: Surendra
authors.initials: S
authors.lastname: Azad
authors.forename: Vivek
authors.initials: V
authors.lastname: Choudhary
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002277:Carcinoma / Q000532:radiotherapy* / Q000556:secondary; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005142:Eyelid Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D016896:Treatment Outcome
chemical_list: D007496:Iridium Radioisotopes